

# MLN120B

Catalog No: tcsc1291



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

783348-36-7

**Formula:**

$C_{19}H_{15}ClN_4O_2$

**Pathway:**

NF-κB

**Target:**

IKK

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 31$  mg/mL (84.51 mM)

**Alternative Names:**

ML120B

**Observed Molecular Weight:**


366.8

## Product Description

MLN120B is a specific, ATP competitive **IKK $\beta$**  inhibitor with an **IC<sub>50</sub>** of 60 nM.

**In Vitro:** MLN120B inhibits both baseline and tumor necrosis factor- $\alpha$ -induced nuclear factor- $\kappa$ B activation, associated with down-regulation of I $\kappa$ B $\alpha$  and p65 nuclear factor- $\kappa$ B phosphorylation in multiple myeloma cells. MLN120B almost completely blocks stimulation of MM.1S, U266, and INA6 cell growth, as well as IL-6 secretion from BMSCs, induced by multiple myeloma cell adherence to BMSCs<sup>[1]</sup>. MLN120B shows an inhibitory effect on LPS induced NF- $\kappa$ B activation in RAW267.4 cells. The IC<sub>50</sub> values of MLN120B is 1.4, 14.8 or 27.3  $\mu$ M for NF- $\kappa$ B2-luc2, IL8-luc2 or TNF-AIP3-luc2 reporter transfected cells, respectively<sup>[3]</sup>.

**In Vivo:** MLN120B (50 mg/kg, p.o.) inhibits human multiple myeloma cell growth in vivo<sup>[1]</sup>. MLN120B (12 mg/kg twice daily, p.o.) inhibits paw swelling in a dose-dependent manner and offers significant protection against arthritis-induced weight loss as well as cartilage and bone erosion. NF- $\kappa$ B activity in arthritic joints is reduced after MLN120B administration<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!